Your browser is no longer supported. Please, upgrade your browser.
SWTX SpringWorks Therapeutics, Inc. daily Stock Chart
SpringWorks Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.60 Insider Own15.58% Shs Outstand41.95M Perf Week-3.44%
Market Cap1.84B Forward P/E- EPS next Y-2.30 Insider Trans0.00% Shs Float32.80M Perf Month-0.02%
Income-68.20M PEG- EPS next Q-0.48 Inst Own81.70% Short Float6.97% Perf Quarter0.92%
Sales- P/S- EPS this Y-176.60% Inst Trans5.86% Short Ratio9.36 Perf Half Y49.14%
Book/sh6.93 P/B6.49 EPS next Y-25.10% ROA-21.00% Target Price54.40 Perf Year87.68%
Cash/sh7.11 P/C6.32 EPS next 5Y- ROE-21.70% 52W Range17.02 - 53.63 Perf YTD16.78%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-16.18% Beta-
Dividend %- Quick Ratio30.80 Sales past 5Y- Gross Margin- 52W Low164.10% ATR3.80
Employees56 Current Ratio30.80 Sales Q/Q- Oper. Margin- RSI (14)50.68 Volatility8.74% 9.11%
OptionableNo Debt/Eq0.00 EPS Q/Q-13.30% Profit Margin- Rel Volume1.08 Prev Close48.21
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume244.22K Price44.95
Recom2.00 SMA201.12% SMA504.79% SMA20023.28% Volume264,039 Change-6.76%
May-05-20Initiated Barclays Overweight $48
Mar-19-20Upgrade H.C. Wainwright Neutral → Buy $40 → $60
Mar-04-20Downgrade H.C. Wainwright Buy → Neutral $40
Jan-21-20Reiterated H.C. Wainwright Buy $34 → $40
Dec-04-19Initiated H.C. Wainwright Buy
Oct-08-19Initiated Wedbush Outperform $33
Oct-08-19Initiated JP Morgan Overweight $32
Oct-08-19Initiated Goldman Buy $37
Oct-08-19Initiated Cowen Outperform
Sep-22-20 04:05PM  
Sep-21-20 07:00AM  
Sep-18-20 06:30AM  
Sep-16-20 06:30AM  
Sep-14-20 06:30AM  
Aug-12-20 04:45PM  
Aug-04-20 06:30AM  
Jul-22-20 06:30AM  
Jun-28-20 04:53PM  
Jun-22-20 09:00AM  
Jun-17-20 08:30AM  
Jun-10-20 06:14AM  
Jun-02-20 06:30AM  
May-26-20 06:30AM  
May-12-20 07:30AM  
Apr-15-20 02:49PM  
Mar-18-20 06:30AM  
Mar-12-20 04:30PM  
Feb-27-20 07:14AM  
Feb-18-20 06:30AM  
Jan-13-20 06:00AM  
Jan-06-20 06:30AM  
Dec-16-19 04:38PM  
Dec-13-19 10:07AM  
Dec-09-19 10:00AM  
Nov-12-19 08:00AM  
Oct-24-19 06:30AM  
Sep-27-19 08:00PM  
Sep-24-19 06:30AM  
Sep-17-19 04:05PM  
Sep-13-19 04:12PM  
Sep-12-19 06:15PM  
SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase IIb clinical trial for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in preclinical trials for the treatment of RRMM. In addition, it is developing Mirdametinib + lifirafenib, a combination therapy that is in Phase Ib clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an investigational oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. SpringWorks Therapeutics, Inc. has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib, as well as medicines; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.